[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592930":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":32,"studyPopulation":32,"armGroups":39,"interventions":46,"overallOfficials":32,"centralContacts":51,"locations":57,"responsibleParty":85,"collaborators":32,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":32,"enrollmentInfo":96,"targetDuration":32,"studyType":99,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":76,"whyStopped":32,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Diagnostic performance","Sensitivity of qualitative assessment of dynamic whole-body \\[68Ga\\]Ga- PSMA PET\u002FCT using standard imaging methods, pathological data if available data or imaging follow-up of at least 6 months as gold standard in two populations of HCC patients: at the time of initial diagnosis or upon detection of suspected refractory, residual, or recurrent relapse.","6 months",[14,18,21,24,26,29],{"measure":15,"description":16,"timeFrame":17},"Kinetic parameters","Patlak's parametric reconstruction, which estimates the 68 Gallium blood input function from the image, will be employed to extract the Ki absorption coefficient.","Baseline",{"measure":19,"description":20,"timeFrame":12},"Diagnostic performance of multiparametric image evaluation approach at the lesion level","Sensitivity value of D-WB \\[68Ga\\]Ga-PSMA PET\u002FCT and gold standard will be calculated and compared at the lesion level.",{"measure":22,"description":23,"timeFrame":12},"Diagnostic performance of multiparametric image evaluation approach at the patient level","Sensitivity value of static \\[68Ga\\]Ga-PSMA PET\u002FCT and Choline-PET will be calculated and compared.",{"measure":22,"description":25,"timeFrame":12},"Sensitivity value of dynamic \\[68Ga\\]Ga-PSMA PET\u002FCT and Choline-PET will be calculated and compared.",{"measure":27,"description":28,"timeFrame":17},"Acceptability in terms of comfort","Acceptability will be measured by a comfort scale from 1 (very uncomfortable) to 5 (very comfortable).",{"measure":30,"description":31,"timeFrame":17},"Dynamic compared to static imaging","Target-to-background ratios (TBR) values were compared with Tumor normalized uptake values (SUV images) to evaluate lesions detection.",null,{"allocation":34,"interventionModel":35,"interventionModelDescription":32,"primaryPurpose":36,"observationalModel":32,"timePerspective":32,"maskingInfo":37},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":38,"maskingDescription":32,"whoMasked":32},"NONE",[40],{"label":41,"type":42,"description":43,"interventionNames":44},"[68Ga]Ga-PSMA","EXPERIMENTAL","Dynamic whole-body \\[68Ga\\]Ga-PSMA acquisition to HCC patients",[45],"Radiation: [68Ga]Ga-PSMA-11",[47],{"type":48,"name":49,"description":43,"armGroupLabels":50,"otherNames":32},"RADIATION","[68Ga]Ga-PSMA-11",[41],[52],{"name":53,"role":54,"phone":55,"phoneExt":32,"email":56},"Clément BAILLY","CONTACT","+33 2 40 08 41 36","clement.bailly@chu-nantes.fr",[58,74],{"facility":59,"status":60,"city":61,"state":32,"zip":32,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"HU Paris Nord APHP","NOT_YET_RECRUITING","Clichy","France","FR",{"type":65,"coordinates":66},"Point",[67,68],2.30952,48.90018,{"lat":68,"lon":67},[71],{"name":72,"role":54,"phone":32,"phoneExt":32,"email":73},"Rachida LEBTAHI","rachida.lebtahi@aphp.fr",{"facility":75,"status":76,"city":77,"state":32,"zip":32,"country":62,"countryCode":63,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"CHU de Nantes","RECRUITING","Nantes",{"type":65,"coordinates":79},[80,81],-1.55336,47.21725,{"lat":81,"lon":80},[84],{"name":53,"role":54,"phone":55,"phoneExt":32,"email":56},{"type":86,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100592930","68gaga-psma-petct-in-hepatocellular-carcinoma-impact-of-multiparametric-dynamic-whole-body-imaging-and-kinetic-modeling-100592930",false,"NCT06999837","[68Ga]Ga-PSMA PET\u002FCT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.","HIMIKO","Inclusion Criteria:\n\n1. Provided written informed consent\n2. Patient aged ≥ 18 years\n3. For cohort A: patient with HCC histologically proven or who meet radiological criteria and are scheduled for biopsy For cohort B: patient with known HCC requiring a new diagnostic imaging workup for suspected refractory, residual or recurrent disease\n4. Presence of at least one morphological evaluable lesion according to mRECIST 1.1 using contrast CT\u002FMRI\n5. Patient must have an ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2\n6. Patient who are Child-Pugh A\n7. Patient must have a life expectancy ≥ 6 months as determined by the study investigator\n8. Patient affiliated to or beneficiary of the National Health Service\n9. Consent to practice double-barrier contraception after \\[68Ga\\]Ga-PSMA injection (6 months of contraception for women study participant and their partners, and 3 months for men study participant and their partners)\n\nExclusion Criteria:\n\n1. Known hypersensitivity to PSMA-11, to any excipient or derivative or to radiographic contrast agents\n2. Patient requiring emergent surgery for a ruptured \u002F bleeding HCC\n3. Radioembolization within 3 months prior to inclusion\n4. Cardiac disease with New York Heart Association classification of III or IV\n5. Any major surgery within 4 weeks before enrollment\n6. Other known malignancies (except for fully-resected non-melanoma skin cancer or cervical cancer in situ) unless definitively treated and proven no evidence of recurrence for 2 years\n7. Any uncontrolled significant medical, psychiatric or surgical condition (active infection (subjects with known human immunodeficiency virus (HIV) positive)), unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension, poorly controlled diabetes mellitus (glycated haemoglobin (HbA1c) ≥9%), uncontrolled congestive heart disease, etc.) or laboratory findings that, in the opinion of the investigator, might jeopardise the subject's safety or that would limit compliance with the objectives and assessments of the study\n8. Woman who are pregnant or breastfeeding. A serum pregnancy test will be performed at the start of the study for all female subjects of childbearing potential\n9. Patient under guardianship or trusteeship\n10. Patient under judicial protection","ALL","18 Years",{"count":97,"type":98},40,"ESTIMATED","INTERVENTIONAL",[34],"The purpose of this study is to evaluate the use of multiparametric dynamic whole-body \\[68Ga\\]Ga-PSMA PET\u002FCT imaging in newly diagnosed HCC patients or in HCC patients with recent suspicion of refractory, residual, or recurrent disease.",[103],"HCC - Hepatocellular Carcinoma",[105,106,107],"68Ga-PSMA PET\u002FCT","Hepatocellular carcinoma","multiparametric dynamic whole-body imaging","2026-09-02",{"date":110,"type":111},"2026-09-03","ACTUAL",{"date":113,"type":111},"2025-09-23",{"date":115,"type":98},"2028-09-23",{"name":5,"class":6},2]